21st Annual Paragraph IV Disputes Conference

Director J.C. Rozendaal will be a panelist during the “Examining How §112 Challenges are Playing Out in Hatch-Waxman Litigation: Key Takeaways for Brands and Generics” session at ACI’s 21st Annual Paragraph IV Disputes Conference. The panel will focus on:

• Examining how §112 is being applied in the District Courts post Amgen v. Sanofi
  • Analyzing patent validity decisions pre and post Amgen
• Exploring opportunities to recapture breadth and scope for brand innovation
• Genus versus species cliams
  • Assessing whether Jepson and means plus function claims are still viable routes
• Exploring how the Federal Circuit discussion on §112 in Teva v. Amneal could impact future Hatch-Waxman litigation for both brands and generics
• Developing strategies for patent drafting through to litigation